Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Revumenib + Azacitidine + Venetoclax in Newly Diagnosed NPM1-mutated or KMT2A-rearranged AML
NCT06652438Phase 3Recruiting
- Sponsor
- HOVON
- Start
- May 2025
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 18
01
Overview
A Phase 3 trial of revumenib in acute myeloid leukemia (AML), sponsored by HOVON. Started May 2025; status: recruiting.
02
Drugs
revumenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06652438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652438.